NEXT Financial Group Inc Purchases 38,600 Shares of BioDelivery Sciences International, Inc. (BDSI)

NEXT Financial Group Inc increased its position in shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) by 55.9% in the 4th quarter, HoldingsChannel reports. The fund owned 107,650 shares of the specialty pharmaceutical company’s stock after buying an additional 38,600 shares during the quarter. NEXT Financial Group Inc’s holdings in BioDelivery Sciences International were worth $398,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. BlackRock Inc. lifted its position in BioDelivery Sciences International by 15.8% during the 4th quarter. BlackRock Inc. now owns 1,388,297 shares of the specialty pharmaceutical company’s stock worth $5,137,000 after buying an additional 189,508 shares in the last quarter. Emerald Mutual Fund Advisers Trust bought a new stake in BioDelivery Sciences International during the 4th quarter worth about $615,000. Emerald Advisers LLC bought a new stake in BioDelivery Sciences International during the 4th quarter worth about $654,000. Alpha Omega Wealth Management LLC lifted its position in BioDelivery Sciences International by 3.1% during the 4th quarter. Alpha Omega Wealth Management LLC now owns 156,739 shares of the specialty pharmaceutical company’s stock worth $4,161,000 after buying an additional 4,677 shares in the last quarter. Finally, Vanguard Group Inc lifted its position in BioDelivery Sciences International by 0.3% during the 3rd quarter. Vanguard Group Inc now owns 2,380,456 shares of the specialty pharmaceutical company’s stock worth $6,666,000 after buying an additional 7,600 shares in the last quarter. Institutional investors and hedge funds own 52.29% of the company’s stock.

Shares of BDSI stock opened at $5.06 on Friday. The company has a quick ratio of 2.77, a current ratio of 3.00 and a debt-to-equity ratio of 1.42. BioDelivery Sciences International, Inc. has a 52-week low of $1.70 and a 52-week high of $5.20.

Several equities research analysts have commented on the stock. Cantor Fitzgerald set a $5.00 price target on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Thursday, December 27th. Zacks Investment Research cut shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research report on Friday, January 18th. Finally, BidaskClub raised shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research report on Friday, December 7th. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $4.75.

In other news, Director Francis E. Odonnell, Jr. sold 8,000 shares of the company’s stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $3.72, for a total value of $29,760.00. Following the sale, the director now directly owns 514,187 shares of the company’s stock, valued at approximately $1,912,775.64. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Paolantonio Ernest Robert De sold 16,161 shares of the company’s stock in a transaction dated Tuesday, December 4th. The shares were sold at an average price of $3.79, for a total transaction of $61,250.19. Following the completion of the sale, the chief financial officer now directly owns 140,548 shares in the company, valued at $532,676.92. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 74,336 shares of company stock worth $306,275. 13.26% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: “NEXT Financial Group Inc Purchases 38,600 Shares of BioDelivery Sciences International, Inc. (BDSI)” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.com-unik.info/2019/03/03/next-financial-group-inc-purchases-38600-shares-of-biodelivery-sciences-international-inc-bdsi.html.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. It focuses on pharmaceutical products in the areas of pain management and addiction. The company was founded on January 6, 1997 and is headquartered in Raleigh, NC.

Further Reading: What are different types of coverage ratios?

Want to see what other hedge funds are holding BDSI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioDelivery Sciences International, Inc. (NASDAQ:BDSI).

Institutional Ownership by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit